The ATM program creates persistent selling pressure as shares can be issued at any time into the market. Combined with the Nasdaq deficiency notice and the China divestiture (which reduces the company's equity stake in SEED), the risk profile has increased materially. Monitor trading volume for ATM sales and any reverse stock split announcement to address the bid price deficiency.
Price Chart
Executive Summary
BeyondSpring Inc. filed a 424B5 prospectus supplement to establish a new at-the-market (ATM) equity offering program for up to 9,200,000 ordinary shares through Citizens JMP Securities. The filing also discloses a Nasdaq minimum bid price deficiency notice received on September 17, 2026, and a China divestiture agreement entered into on September 28, 2026, where the company will sell its Chinese subsidiary in exchange for the investor funding the China portion of the DUBLIN-4 trial. The ATM program creates ongoing dilution overhang for a pre-revenue biotech trading near $0.78, while the Nasdaq deficiency adds delisting risk.
Key Facts
- New ATM facility for up to 9,200,000 ordinary shares (23% of ~40M shares outstanding) via Citizens JMP Securities, capped at $11,942,800 aggregate offering price due to public float limitations.
- Last reported stock price on September 25, 2026 was $0.7772 per share; gross proceeds at that price would be ~$7.15 million.
- Received Nasdaq deficiency notice on September 17, 2026 for bid price closing below $1.00 for 30 consecutive business days; has until March 16, 2027 to regain compliance.
- Entered into China divestiture agreement on September 28, 2026 to sell Chinese subsidiary in exchange for investor funding the China portion of DUBLIN-4 trial; indirect equity interest in SEED Therapeutics will be reduced.
- Net tangible book value as of June 30, 2026 was negative $(36.03) million, or $(0.88) per share; after full ATM issuance, adjusted book value would be $(0.58) per share.
- Prior 2019 ATM program with Jefferies was terminated effective September 9, 2026; 630,228 shares had been sold under that program.
- Company is a clinical-stage biopharma with no approved products and no revenue from product sales.
Financial Impact
Potential gross proceeds up to ~$7.15 million at current price; dilution of up to 23% of outstanding shares. Net tangible book value per share would improve from $(0.88) to $(0.58), but new investors face $1.36 per share dilution.
Risk Factors
- Nasdaq delisting if bid price does not recover above $1.00 by March 16, 2027.
- Ongoing dilution from ATM sales at depressed prices near $0.78.
- China divestiture reduces indirect ownership in SEED Therapeutics, removing a potential value driver.
- Clinical-stage biotech with no approved products and negative book value; high cash burn risk.
- PFIC status uncertainty may deter certain U.S. institutional investors.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001140361-26-037918 |
| Document: 0001140361-26-037918-index-headers.html | 0001140361-26-037918 |
| Document: 0001140361-26-037918-index.html | 0001140361-26-037918 |
| Document: 0001140361-26-037918.txt | 0001140361-26-037918 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4600 (−28.68%) |
Oct 2, 2026 24d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4600 (+41.48%) |
Sep 29, 2026 27d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4600 (−40.51%) |
Sep 29, 2026 27d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4600 (+40.51%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4600 (+37.84%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4600 (−25.58%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4600 (−35.35%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4600 (−35.35%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4600 (−73.10%) |
Jun 2, 2026 20w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4600 (−72.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers